
National Health Act 1953
I, Rebecca Richardson, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following determination.
REBECCA RICHARDSON
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
1 Name
(1) This instrument is the National Health (April 2026 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2026.
(2) This instrument may also be cited as PB 10 of 2026.
2 Commencement
This instrument commences on 1 April 2026.
3 Authority
This instrument is made under subsection 99ACF(3) of the National Health Act 1953.
4 Definition
Note: A number of expressions used in this instrument are defined in Part VII the Act.
In this instrument:
Act means the National Health Act 1953.
Reduction day in this instrument refers to 1 April 2026.
5 Brand of pharmaceutical item not subject to a price reduction
I determine, under paragraph 99ACF(3)(a) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is not reduced under a provision mentioned in item 2A or item 3A or item 4A of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the reduction day.
6 Brand of pharmaceutical item subject to a lower price reduction than would otherwise apply
I determine, under paragraph 99ACF(3)(b) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of a brand of pharmaceutical item specified in column 2 of an item in the table in Schedule 2 is reduced under a provision mentioned in item 4A of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the reduction day by the percentage specified in column 3 of the table item.
Schedule 1 — Brands of pharmaceutical items with approved ex-manufacturer price not reduced
Column 1 | Column 2 | |||
Item | Brand of Pharmaceutical Item | |||
| Drug | Form | Manner of administration | Brand(s) |
1 | Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides | Oral powder 400 g (Essential Care Jr)
| Oral | Essential Care Jr
|
2 | Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides | Oral powder 400 g (Neocate Junior) | Oral | Neocate Junior |
3 | Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides | Oral powder 400 g (Neocate Gold) | Oral | Neocate Gold
|
4 | Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides | Oral powder with 2'-fucosyllactose and lacto-N-neotetraose, 400 g (Alfamino) | Oral | Alfamino |
5 | Azacitidine | Tablet 200 mg | Oral | Onureg |
6 | Azacitidine | Tablet 300 mg | Oral | Onureg |
7 | Cetrorelix | Powder for injection 250 micrograms (as acetate) with diluent | Injection | Cetrotide |
8 | Citrulline with carbohydrate | Sachets of oral powder 4 g containing 1 g citrulline, 30 (Citrulline 1000) | Oral | Citrulline 1000 |
9 | Degarelix | Powder for injection 80 mg (as acetate), injection set | Injection | Firmagon 80 mg |
10 | Degarelix | Powder for injection 120 mg (as acetate), 2, injection set | Injection | Firmagon 120 mg |
11 | Dupilumab | Injection 200 mg in 1.14 mL single dose pre-filled syringe | Injection | Dupixent |
12 | Dupilumab | Injection 200 mg in 1.14 mL single dose pre-filled pen | Injection | Dupixent |
13 | Dupilumab | Injection 300 mg in 2 mL single dose pre-filled syringe | Injection | Dupixent |
14 | Dupilumab | Injection 300 mg in 2 mL single dose pre-filled pen | Injection | Dupixent |
15 | Eletriptan | Tablet 40 mg (as hydrobromide) | Oral | Relpax |
16 | Eletriptan | Tablet 80 mg (as hydrobromide) | Oral | Relpax |
17 | Febuxostat | Tablet 80 mg | Oral | Adenuric |
18 | Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 20 mg | Oral | Vyvanse |
19 | Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 30 mg | Oral | Vyvanse |
20 | Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 40 mg | Oral | Vyvanse |
21 | Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 50 mg | Oral | Vyvanse |
22 | Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 60 mg | Oral | Vyvanse |
23 | Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 70 mg | Oral | Vyvanse |
24 | Lutropin alfa | Powder for injection 75 I.U. with solvent | Injection | Luveris |
25 | Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A | Oral liquid 125 mL, 24 (Renastep) | Oral | Renastep |
26 | Romiplostim
| Powder for injection 375 micrograms | Injection
| Nplate |
27 | Romiplostim
| Powder for injection 625 micrograms | Injection | Nplate |
28 | Romosozumab | Injection 105 mg in 1.17 mL single use pre-filled syringe | Injection | |
29 | Semaglutide | Solution for injection 2 mg in 1.5 mL pre-filled pen | Injection | Ozempic |
30 | Semaglutide | Solution for injection 2 mg in 3 mL pre-filled pen | Injection | Ozempic |
31 | Semaglutide | Solution for injection 4 mg in 3 mL pre-filled pen | Injection | Ozempic |
32 | Stiripentol | Capsule 250 mg | Oral | Diacomit |
33 | Stiripentol | Capsule 500 mg | Oral | Diacomit |
34 | Stiripentol | Powder for oral suspension 250 mg | Oral | Diacomit |
35 | Stiripentol | Powder for oral suspension 500 mg | Oral | Diacomit |
36 | Trametinib | Powder for oral solution 50 micrograms per mL (as dimethylsulfoxide), 90 mL | Oral | Mekinist |
Schedule 2 — Brands of pharmaceutical items with approved ex-manufacturer price reduced by a lower percentage than would otherwise apply
Column 1 | Column 2 | Column 3 | |||
Item | Brand of pharmaceutical item | % reduction | |||
| Drug | Form | Manner of administration | Brand |
|
1 | Golimumab | Injection 50 mg in 0.5 mL single use pre-filled syringe | Injection | Simponi | 10% |
2 | Golimumab | Injection 50 mg in 0.5 mL single use pre-filled pen | Injection | Simponi | 10% |
3 | Golimumab | Injection 100 mg in 1 mL single use pre-filled pen | Injection | Simponi | 10% |